Hematology 64th American Society of Hematology (ASH) Annual Meeting: Expert Interview Dr. Dennis Kim — Length: 05:18 STAMP Inhibitor Broadens the Treatment Landscape in Chronic Myeloid Leukemia Watch Presentation
Hematology 64th American Society of Hematology (ASH) Annual Meeting and Exposition December 10-13, 2022 — New Orleans, Louisiana Novel Small Molecule Inhibitor Broadens the Treatment Landscape in Chronic Myeloid Leukemia Download 4 PowerPoint slides
Hematology 64th American Society of Hematology (ASH) Annual Meeting: Expert Interview Dr. Laurie H. Sehn — Length: 05:00 New Data Shifts Risk-benefit of BTK Inhibitors in CLL/SLL Watch Presentation
Hematology 2022 European Hematology Association (EHA) Congress Dr. Carolyn Owen — Length: 05:14 Long-term ASPEN Data: Demonstrated Efficacy and Tolerability in Patients with Waldenström Macroglobulinemia Watch Presentation
Hematology American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Dr. Versha Banerji — Length: 04:15 Continued Benefit for First-line CLL Treatment: ELEVATE-TN 5-year Follow-up Watch Presentation
Hematology American Society of Clinical Oncology (ASCO) 2022 Annual Meeting June 3-7, 2022 — Chicago, Illinois ELEVATE-TN: At 5 Years, Progression-free Survival with High Tolerability Maintained in Treatment-naïve CLL Patients Download 4 PowerPoint slides
Hematology American Society of Clinical Oncology (ASCO) 2022 Annual Meeting June 3-7, 2022 — Chicago, Illinois ASPEN Study: Long-Term Clinical Advantages of a Newer BTK Inhibitor in Waldenström Macroglobulinemia Confirmed Download 6 PowerPoint slides
Hematology 63rd American Society of Hematology (ASH) Annual Meeting: Expert Interview Dr. Christine I. Chen — Length: 08:52 Latest Data Reinforce ASPEN Study Results on BTK Specificity in WM Watch Presentation
Hematology 63rd American Society of Hematology (ASH) Annual Meeting and Exposition December 11-14, 2021 — Atlanta, Georgia BTK Inhibitor Paradigm Shift in Waldenström Macroglobulinemia: Clinical Implications Download 4 PowerPoint slides
Hematology American Society of Clinical Oncology (ASCO) 2021 Annual Meeting: Expert Interview Dr. Versha Banerji — Length: 10:57 Effective Treatment Option for CLL: Clinical Implications of the ELEVATE Trials Watch Presentation
Hematology American Society of Clinical Oncology (ASCO) 2021 Annual Meeting June 4-8, 2021 — Virtual Meeting New Data from Head-to-head and Long-term Follow-up BTK Inhibitor Trials Clarify Choices in CLL Download 6 PowerPoint slides
Hematology 25th European Hematology Association Congress (EHA25 Virtual) June 11-14, 2020 — Virtual Meeting Next-Generation BTK Inhibitors Fulfilling Promise for CLL in Long-Term Follow-Up Download 3 PowerPoint slides